MPCCC Precision Oncology Seminars illuminate ways to tackle rare and aggressive cancers

The MPCCC Precision Oncology Program welcomed two eminent speakers in August and September 2019 to present at Precision Oncology Seminars. These seminars brought together researchers and clinicians from across MPCCC partners to hear how precision oncology techniques can enable effective individualised treatments for rare and aggressive cancers. Dr Richard Tothill, Head [...]

2020-04-04T12:12:20+11:00October 21st, 2019|

MPCCC’s Molecular Tumour Boards and Precision Oncology Seminars drive innovation in personalised cancer treatment

Since its commencement in September 2018, the MPCCC Precision Oncology Program has established regular Molecular Tumour Board meetings that focus on three distinct tumour streams. “Our Molecular Tumour Boards have been successful in creating space for discussions about selection of therapies based on genomic tumour profiling, in patients whose cancers [...]

2020-04-04T12:12:54+11:00July 8th, 2019|

Eminent Australian Prof David Thomas delivers MPCCC’s March Precision Oncology Seminar

Prof David Thomas, Director of the Kinghorn Cancer Centre, Founder of the Australian Cancer Genomics Medicine Programme, and arguably Australia’s leader in precision oncology, captivated attendees at the MPCCC’s March Precision Oncology Session with his presentation of the progress and potential of this field. Prof Thomas revealed to stakeholders that [...]

2020-04-04T12:13:19+11:00March 22nd, 2019|

MPCCC to Launch a Network of Precision Oncology Tumour Boards and Seminars

A network of tumour-specific MPCCC Precision Oncology Tumour Boards will be rolled out across MPCCC partner sites in early 2019 thanks to funding received from the Victorian Cancer Agency. “The primary aim of establishing MPCCC’s network of Precision Oncology Tumour Boards is to integrate the considerable clinical, molecular and research [...]

2020-04-04T12:13:41+11:00December 12th, 2018|

Treatment for Cancer Patients to Improve with MPCCC’s New Precision Oncology Tumour Board

Cancer patients treated at Monash Partners’ hospitals will have equitable access to the latest precision medicine technologies, and the best medical advice and treatments thanks to a new Precision Oncology Tumour Board, to be established by the Monash Partners Comprehensive Cancer Consortium (MPCCC). Collectively MPCCC partners care for over 19,000 [...]

2020-04-04T12:13:51+11:00May 11th, 2018|
Go to Top